Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Division of Life Sciences and Medicine, Department of Pathology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Cancer Med. 2024 Aug;13(16):e70100. doi: 10.1002/cam4.70100.
Glioblastoma (GBM) is the most aggressive of intracranial gliomas. Despite the maximal treatment intervention, the median survival rate is still about 14-16 months. Nuclear receptor-binding protein 1 (NRBP1) has a potential growth-promoting role on biology function of cells. In this study, we investigated whether NRBP1 promotes GBM malignant phenotypes and the potential mechanisms.
The correlation between NRBP1 and glioma grade, prognosis in TCGA/CGGA databases and our clinical data were analyzed. Next, we conducted knockout and overexpression of NRBP1 on GBM cells to verify that NRBP1 promoted cell proliferation, invasion, and migration in vitro and in vivo. Finally, we detected the impact of NRBP1 on PI3K/Akt signaling pathway and EMT.
There was a correlation between elevated NRBP1 expression and advanced stage glioma, as well as decreased overall and disease-free survival. The suppression of proliferation, invasion, and migration of tumor cells was observed upon NRBP1 knockout, and in vitro studies also demonstrated the induction of apoptotic cell death. Whereas, its overexpression is associated with high multiplication rate, migration, invasion, and apoptotic escape. GO enrichment and KEGG analysis revealed that NRBP1 regulated differentially expressed gene clusters are involved in PI3K/Akt signaling pathway, as well as EMT mediated by this pathway. Moreover, the effects of NRBP1 knockdown and overexpression on GBM were mitigated by MK-2206 and SC79, both of which respectively function as an inhibitor and an activator of the PI3K/Akt signaling pathway. Similarly, the suppression of NRBP1 led to a decrease in tumor growth, whereas its overexpression promoted tumor growth in a mouse model.
This study shows that NRBP1 promotes malignant phenotypes in GBM by activating PI3K/Akt pathway. Hence, it can function as both a predictive indicator and a new target for therapies in GBM treatment.
胶质母细胞瘤(GBM)是颅内胶质瘤中最具侵袭性的一种。尽管采用了最大的治疗干预措施,中位生存率仍约为 14-16 个月。核受体结合蛋白 1(NRBP1)在细胞生物学功能上具有潜在的促进生长作用。在本研究中,我们研究了 NRBP1 是否促进 GBM 恶性表型及其潜在机制。
分析 NRBP1 与 TCGA/CGGA 数据库中脑胶质瘤分级、预后的相关性以及我们的临床数据。接下来,我们在 GBM 细胞中进行 NRBP1 的敲除和过表达,以验证 NRBP1 是否促进细胞在体外和体内的增殖、侵袭和迁移。最后,我们检测了 NRBP1 对 PI3K/Akt 信号通路和 EMT 的影响。
NRBP1 表达升高与高级别胶质瘤以及总生存期和无病生存期缩短相关。NRBP1 敲除后观察到肿瘤细胞增殖、侵袭和迁移受到抑制,体外研究也表明诱导细胞凋亡。相反,过表达与高倍增率、迁移、侵袭和凋亡逃逸有关。GO 富集和 KEGG 分析表明,NRBP1 调节差异表达基因簇参与 PI3K/Akt 信号通路以及该通路介导的 EMT。此外,MK-2206 和 SC79 分别作为 PI3K/Akt 信号通路的抑制剂和激活剂,可减轻 NRBP1 敲低和过表达对 GBM 的影响。同样,抑制 NRBP1 导致肿瘤生长减少,而过表达则促进肿瘤在小鼠模型中的生长。
本研究表明,NRBP1 通过激活 PI3K/Akt 通路促进 GBM 的恶性表型。因此,它可以作为 GBM 治疗的预测指标和新靶点。